FDA report a setback for J&J clotting drug
Urges rejection of Xarelto, citing need for more data
TRENTON, N.J. - A negative review from Food and Drug Administration staff bodes ill for a new blood thinner from Johnson & Johnson.
An FDA staff report released yesterday recommends against approving Xarelto for preventing strokes in patients with a common irregular heart rhythm called atrial fibrillation. It says an additional study is needed.
The report states that data from a late-stage study of more than 14,000 patients, known by the acronym ROCKET, do not make clear how safe Xarelto is, or whether it is as effective as widely used warfarin.
Johnson & Johnson and partner Bayer Healthcare of Germany developed the drug, known chemically as rivaroxaban.
“ROCKET does not show convincingly that rivaroxaban is as effective as warfarin when the latter is used skillfully,’’ states the 388-page report by three FDA staff reviewers.
The report adds that there are several reasons to deny the makers’ request to include a contention in the detailed package insert that Xarelto is superior to warfarin. Among the reasons, it says such an assertion “might induce physicians to switch patients who are doing well on warfarin to rivaroxaban.’’
Xarelto was approved in July for reducing the risk of deadly blood clots in patients getting knee and hip replacements, a small part of the potential patient pool. That approval followed a delay of roughly two years because of FDA concerns about internal bleeding risk - a side effect listed on the package insert along with itching, muscle pain, blisters, and fainting.
Tomorrow, A panel of outside advisers to the FDA is set to review data on use of Xarelto in patients with atrial fibrillation, including the staff report and a presentation by the makers. The advisers will then vote whether to recommend that the agency approve it.
They could urge an additional patient study be done, which would cause a long delay before the drug makers could again seek approval. FDA officials often follow advisers’ recommendations, but are not obligated to do so.
“We now see a first-time approval as being unlikely,’’ Jerffries Research analyst Jeffrey Holford wrote to investors. He noted the staff comments “point to poor clinical trial design.’’
“We’re confident in the effectiveness of rivaroxaban in preventing strokes in patients with atrial fibrillation and look forward to presenting our data to address the FDA’s questions on Thursday,’’ said a Johnson & Johnson spokesman, Ernie Kniewitz. “In our book, we’ve laid out a lot of points that support the effectiveness of rivaroxaban.’’
Bayer Healthcare already markets rivaroxaban in 110 countries.
The daily pill works by blocking a clotting protein called factor Xa. Older blood thinners, including warfarin, work by preventing platelets from sticking together.
Warfarin, sold as Coumadin and other brands, has its own drawbacks. It is notoriously difficult to get the dose of the drug correct, so patients need frequent blood tests because too much warfarin can cause dangerous internal bleeding.
That has made a replacement for inexpensive warfarin a key goal for numerous drug makers. Last October, the FDA approved the first alternative to warfarin for atrial fibrillation - Pradaxa, known chemically as dabigatran, made by the German company Boehringer Ingelheim.
Johnson & Johnson shares closed $0.57 up at $64.64.